Synovus Financial Corp Purchases 1,346 Shares of Insulet Corporation $PODD

Key Points

• Synovus Financial Corp increased its holdings in Insulet Corporation by 45.4% in the first quarter, now owning 4,310 shares valued at approximately $1.13 million.
• Insulet's stock has seen a price increase, currently trading at $331.83 after reporting a 32.9% year-over-year revenue growth of $649.10 million for the last quarter.
• Wall Street analysts have rated Insulet positively, with 16 analysts giving it a "Buy" rating and price targets ranging as high as $380.00.

Synovus Financial Corp raised its stake in Insulet Corporation (NASDAQ:PODD - Free Report) by 45.4% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 4,310 shares of the medical instruments supplier's stock after purchasing an additional 1,346 shares during the period. Synovus Financial Corp's holdings in Insulet were worth $1,132,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Vanguard Group Inc. increased its holdings in shares of Insulet by 2.1% in the first quarter. Vanguard Group Inc. now owns 8,668,952 shares of the medical instruments supplier's stock valued at $2,276,553,000 after purchasing an additional 178,976 shares during the last quarter. American Century Companies Inc. raised its holdings in Insulet by 34.8% in the 1st quarter. American Century Companies Inc. now owns 1,152,606 shares of the medical instruments supplier's stock valued at $302,686,000 after acquiring an additional 297,734 shares during the period. Groupama Asset Managment raised its holdings in Insulet by 0.4% in the 1st quarter. Groupama Asset Managment now owns 1,053,759 shares of the medical instruments supplier's stock valued at $276,728,000 after acquiring an additional 3,759 shares during the period. Northern Trust Corp raised its holdings in Insulet by 20.5% in the 4th quarter. Northern Trust Corp now owns 738,811 shares of the medical instruments supplier's stock valued at $192,881,000 after acquiring an additional 125,710 shares during the period. Finally, Charles Schwab Investment Management Inc. raised its holdings in Insulet by 4.2% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 674,367 shares of the medical instruments supplier's stock valued at $177,096,000 after acquiring an additional 27,408 shares during the period.

Insulet Stock Performance

Shares of Insulet stock traded up $2.28 during trading on Monday, reaching $339.88. The company's stock had a trading volume of 515,158 shares, compared to its average volume of 702,791. Insulet Corporation has a 52 week low of $199.68 and a 52 week high of $341.14. The business's 50-day moving average price is $304.04 and its 200-day moving average price is $287.71. The company has a quick ratio of 1.81, a current ratio of 2.26 and a debt-to-equity ratio of 0.64. The firm has a market cap of $23.93 billion, a PE ratio of 103.31, a P/E/G ratio of 2.85 and a beta of 1.36.

Insulet (NASDAQ:PODD - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share for the quarter, topping the consensus estimate of $0.92 by $0.25. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The business had revenue of $649.10 million during the quarter, compared to analysts' expectations of $612.31 million. During the same quarter in the prior year, the business posted $0.55 earnings per share. Insulet's revenue was up 32.9% compared to the same quarter last year. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. Equities analysts forecast that Insulet Corporation will post 3.92 earnings per share for the current year.

Analyst Upgrades and Downgrades

PODD has been the topic of several research analyst reports. Morgan Stanley reissued an "overweight" rating on shares of Insulet in a report on Thursday, August 7th. Truist Financial began coverage on shares of Insulet in a research report on Monday, June 16th. They issued a "buy" rating and a $365.00 target price for the company. Jefferies Financial Group reissued a "buy" rating on shares of Insulet in a research report on Thursday, August 7th. Oppenheimer boosted their target price on shares of Insulet from $312.00 to $324.00 and gave the company an "outperform" rating in a research report on Friday, May 9th. Finally, Wall Street Zen raised shares of Insulet from a "hold" rating to a "buy" rating in a research report on Saturday, August 9th. Sixteen analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $332.71.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.